High expression of excision repair cross-complementation group1 protein predicts poor outcome in patients with nasopharyngeal cancer

Oral Oncology

Volumn 46, Issue 3, 2010, Pages 209-213

  Lee, Hyun Woo ^a   Hwang, Yoon Ho ^a   Han, Jae Ho ^a   Choi, Jin Hyuk ^a   Kang, Seok Yun ^a   Jeong, Seong Hyun ^a   Ann, Mi Sun ^a   Oh, Young Taek ^a   Kim, Jang Hee ^a   Kim, Chul Ho ^a   Sheen, Seung Soo ^a  

^a Ajou University School of Medicine   (South Korea)

Author keywords

Chemoradiotherapy; Cisplatin; ERCC1; Nasopharyngeal cancer; Prognostic factor

Indexed keywords

CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; THYMIDYLATE SYNTHASE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NASOPHARYNX CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE; TREATMENT OUTCOME; TUMOR BIOPSY;

ADULT; AGED; ASIA, SOUTHEASTERN; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM PROTEINS; PROGNOSIS; THYMIDYLATE SYNTHASE; YOUNG ADULT;

EID: 76749158391     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2009.12.007     Document Type: Article

References (32)

1. Cancer incidence in five continents, vol. VII. IARC Sci. Publ.; 1997(143). p. i-xxxiv, 1-1240.
2. Chan A.T., Teo P.M., and Johnson P.J. Nasopharyngeal carcinoma. Ann Oncol 13 7 (2002) 1007-1015
3. Lin J.C., Jan J.S., Hsu C.Y., Liang W.M., Jiang R.S., and Wang W.Y. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol 21 4 (2003) 631-637
4. Langendijk J.A., Leemans C.R., Buter J., Berkhof J., and Slotman B.J. The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta-analysis of the published literature. J Clin Oncol 22 22 (2004) 4604-4612
5. Al-Sarraf M., LeBlanc M., Giri P.G., Fu K.K., Cooper J., Vuong T., et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 16 4 (1998) 1310-1317
6. Kwong D.L., Sham J.S., Au G.K., Chua D.T., Kwong P.W., Cheng A.C., et al. Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study. J Clin Oncol 22 13 (2004) 2643-2653
7. Wee J., Tan E.H., Tai B.C., Wong H.B., Leong S.S., Tan T., et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol 23 27 (2005) 6730-6738
8. Chan A.T., Leung S.F., Ngan R.K., Teo P.M., Lau W.H., Kwan W.H., et al. Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst 97 7 (2005) 536-539
9. Guigay J. Advances in nasopharyngeal carcinoma. Curr Opin Oncol 20 3 (2008) 264-269
10. Reed E. ERCC1 and clinical resistance to platinum-based therapy. Clin Cancer Res 11 17 (2005) 6100-6102
11. Olaussen K.A., Dunant A., Fouret P., Brambilla E., Andre F., Haddad V., et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355 10 (2006) 983-991
12. Murray D., Vallee-Lucic L., Rosenberg E., and Andersson B. Sensitivity of nucleotide excision repair-deficient human cells to ionizing radiation and cyclophosphamide. Anticancer Res 22 1A (2002) 21-26
13. Murray D., Macann A., Hanson J., and Rosenberg E. ERCC1/ERCC4 5'-endonuclease activity as a determinant of hypoxic cell radiosensitivity. Int J Radiat Biol 69 3 (1996) 319-327
14. Pinedo H.M., and Peters G.F. Fluorouracil: biochemistry and pharmacology. J Clin Oncol 6 10 (1988) 1653-1664
15. Boku N., Chin K., Hosokawa K., Ohtsu A., Tajiri H., Yoshida S., et al. Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with 5-fluorouracil and cis-platinum. Clin Cancer Res 4 6 (1998) 1469-1474
16. Shirota Y., Stoehlmacher J., Brabender J., Xiong Y.P., Uetake H., Danenberg K.D., et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 19 23 (2001) 4298-4304
17. Yasumatsu R., Nakashima T., Uryu H., Ayada T., Wakasaki T., Kogo R., et al. Correlations between thymidylate synthase expression and chemosensitivity to 5-fluorouracil, cell proliferation and clinical outcome in head and neck squamous cell carcinoma. Chemotherapy 55 1 (2009) 36-41
18. Kang S.Y., Oh Y.T., Han J.H., Choi J.H., Lim H.Y., Kim H.I., et al. Concurrent chemoradiotherapy in patients with nasopharyngeal cancer: prognostic significance of low expression of bax. Neoplasma 53 5 (2006) 450-456
19. Greene F.L. AJCC cancer staging manual. 6 ed. (2002), Springer, New York
20. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 3 (2000) 205-216
21. Kaplan E., and Meier P. Non-parametric estimations from incomplete observations. J Am Statistical Assoc 53 (1958) 457-481
22. Cox D.R. Regression model and life-tables. J Roy Statist Soc Ser 34 (1972) 187-220
23. Ou S.H., Zell J.A., Ziogas A., and Anton-Culver H. Epidemiology of nasopharyngeal carcinoma in the United States: improved survival of Chinese patients within the keratinizing squamous cell carcinoma histology. Ann Oncol 18 1 (2007) 29-35
24. Nakao K., Mochiki M., Nibu K., Sugasawa M., and Uozaki H. Analysis of prognostic factors of nasopharyngeal carcinoma: impact of in situ hybridization for Epstein-Barr virus encoded small RNA 1. Otolaryngol Head Neck Surg 134 4 (2006) 639-645
25. Vaughan T.L., Shapiro J.A., Burt R.D., Swanson G.M., Berwick M., Lynch C.F., et al. Nasopharyngeal cancer in a low-risk population: defining risk factors by histological type. Cancer Epidemiol Biomarkers Prev 5 8 (1996) 587-593
26. Lee H.W., Han J.H., Kim J.H., Lee M.H., Jeong S.H., Kang S.Y., et al. Expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with small cell lung cancer. Lung Cancer 59 1 (2008) 95-104
27. Joshi M.B., Shirota Y., Danenberg K.D., Conlon D.H., Salonga D.S., Herndon II J.E., et al. High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res 11 6 (2005) 2215-2221
28. Metzger R., Leichman C.G., Danenberg K.D., Danenberg P.V., Lenz H.J., Hayashi K., et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 16 1 (1998) 309-316
29. Handra-Luca A., Hernandez J., Mountzios G., Taranchon E., Lacau-St-Guily J., Soria J.C., et al. Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma. Clin Cancer Res 13 13 (2007) 3855-3859
30. Jun H.J., Ahn M.J., Kim H.S., Yi S.Y., Han J., Lee S.K., et al. ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation. Br J Cancer 99 1 (2008) 167-172
31. Yang Z.H., Dai Q., Kong X.L., Yang W.L., and Zhang L. Association of ERCC1 polymorphisms and susceptibility to nasopharyngeal carcinoma. Mol Carcinog 48 3 (2009) 196-201
32. Ma B.B., Hui E.P., Wong S.C., Tung S.Y., Yuen K.K., King A., et al. Multicenter phase II study of gemcitabine and oxaliplatin in advanced nasopharyngeal carcinoma-correlation with excision repair cross-complementing-1 polymorphisms. Ann Oncol 20 11 (2009) 1854-1859